Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: Could we stop the treatment? About four cases

Florian PoullenotDepartment of Gastroenterology and Hepatology, Saint-André Hospital, University Hospital of Bordeaux and Victor Segalen University, Bordeaux, France

Paulette Bioulac-SageDepartment of Pathology, Pellegrin Hospital, University Hospital of Bordeaux and Victor Segalen University, Bordeaux, France

Hervé LaumonierDepartment of Radiology, Saint André Hospital, University Hospital of Bordeaux, and Victor Segalen University, Bordeaux, France

Jean SaricDepartment of Digestive Surgery, Saint André Hospital, University Hospital of Bordeaux and Victor Segalen University, Bordeaux, France

Thibault CarteretDepartment of Radiology, Saint André Hospital, University Hospital of Bordeaux, and Victor Segalen University, Bordeaux, France

Jean-Frédéric BlancDepartment of Gastroenterology and Hepatology, Saint-André Hospital, University Hospital of Bordeaux and Victor Segalen University, Bordeaux, FranceCorrespondence[email protected]

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Hibiki Narita, Hideto Kawaratani, Akihiko Shibamoto, Soichi Takeda, Takahiro Ozutsumi, Yuki Tsuji, Yukihisa Fujinaga, Koh Kitagawa, Norihisa Nishimura, Daisuke Hokuto, Masayuki Sho & Hitoshi Yoshiji. (2022) Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report. Clinical Journal of Gastroenterology 15:5, pages 953-959.
Crossref

Kush Fansiwala, Jason Saltiel & Michael Poles. (2021) Acute Kidney Injury Presenting as Hepatorenal Syndrome in the Setting of Glecaprevir/Pibrentasvir Treatment for Hepatitis C. ACG Case Reports Journal 8:5, pages e00587.
Crossref

Dong Hyun Kim, Eunae Cho, Sung Bum Cho, Sung Kyu Choi, Sunmin Kim, Jieun Yu, Young-Il Koh, Da Woon Sim & Chung Hwan Jun. (2018) Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell). Medicine 97:42, pages e12866.
Crossref

Teng-Yu Lee, Chen-Chun Lin, Chiung-Yu Chen, Tsang-En Wang, Gin-Ho Lo, Chi-Sen Chang & Yee Chao. (2017) Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early–intermediate stage hepatocellular carcinoma. Medicine 96:37, pages e7655.
Crossref

Norihito Nakano, Tomokazu Kawaoka, Hiroshi Aikata, Fumi Honda, Yuki Nakamura, Kei Morio, Masahiro Hatooka, Takayuki Fukuhara, Tomoki Kobayashi, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Shoichi Takahashi & Kazuaki Chayama. (2016) Complete response to short-term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases. Hepatology Research 46:13, pages 1402-1408.
Crossref

Atilla ArslanogluAdeel R. SeyalFaezeh SodagariAzize SahinFrank H. MillerRiad SalemVahid Yaghmai. (2016) Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review. American Journal of Roentgenology 207:5, pages W88-W98.
Crossref

. (2014) Sorafenib. Reactions Weekly 1496:1, pages 37-37.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: Could we stop the treatment? About four cases

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: Could we stop the treatment? About four cases

Citations (7)

Articles from other publishers (7)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date